Novo Nordisk A/S $NVO Shares Purchased by Bangor Savings Bank

Bangor Savings Bank raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 64.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 27,971 shares of the company’s stock after purchasing an additional 10,969 shares during the quarter. Bangor Savings Bank’s holdings in Novo Nordisk A/S were worth $1,552,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Kingstone Capital Partners Texas LLC increased its position in Novo Nordisk A/S by 301,443.6% in the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after acquiring an additional 10,001,898 shares during the period. SG Americas Securities LLC lifted its position in Novo Nordisk A/S by 2,101.5% during the 3rd quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock worth $132,242,000 after acquiring an additional 2,274,925 shares during the period. Bank of Montreal Can grew its stake in shares of Novo Nordisk A/S by 101.4% in the 2nd quarter. Bank of Montreal Can now owns 2,475,300 shares of the company’s stock valued at $170,845,000 after purchasing an additional 1,246,467 shares during the last quarter. DAVENPORT & Co LLC increased its holdings in shares of Novo Nordisk A/S by 54.8% in the third quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company’s stock valued at $146,644,000 after purchasing an additional 935,468 shares during the period. Finally, Sustainable Growth Advisers LP raised its stake in shares of Novo Nordisk A/S by 11.7% during the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after purchasing an additional 649,390 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

NVO opened at $59.83 on Tuesday. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $93.80. The stock has a market cap of $267.12 billion, a P/E ratio of 17.39 and a beta of 0.66. The stock’s 50 day simple moving average is $49.87 and its 200 day simple moving average is $55.15. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The company had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on NVO. Morgan Stanley reiterated an “underweight” rating and issued a $42.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. Rothschild & Co Redburn upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 16th. The Goldman Sachs Group lowered their target price on shares of Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating on the stock in a report on Friday, November 28th. Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, December 29th. Finally, Berenberg Bank upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, eleven have issued a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $56.21.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: U.S. oral Wegovy rollout broadens commercial reach: Novo has launched its oral GLP‑1 (the “Wegovy Pill”) across a wide pharmacy network, making it the first oral weight‑loss GLP‑1 widely available in the U.S.; that distribution scale supports faster adoption and incremental sales versus an injection‑only offering. Read More.
• Positive Sentiment: Management sees a bigger oral market long term: Novo executives now expect oral GLP‑1 pills to capture over one‑third of the GLP‑1 market by 2030, implying a larger addressable market and more diverse revenue mix than previously modeled. That raises longer‑term revenue potential and reduces single‑product concentration risk. Read More.
• Positive Sentiment: Behavioral/health spillovers bolster product narrative: Research linking GLP‑1 receptor agonists to lower household spending on alcohol and tobacco supports a broader public‑health and societal value story that can aid payer conversations and public acceptance. Read More.
• Neutral Sentiment: Unusual options activity signals trader interest but not direction: Elevated/options flows show speculative positioning or hedging ahead of catalysts (sales data, guidance, regulation); could increase volatility in the short term without indicating a definitive fundamental shift. Read More.
• Neutral Sentiment: Increased analyst and fund attention raises visibility: Coverage from Fundsmith, Zacks and healthcare ETF narratives is driving investor focus on NVO (both positive for liquidity and sentiment but mixed on valuation). Monitor earnings/sales prints and guidance for conviction. Read More.
• Negative Sentiment: Compounded GLP‑1s pose a near‑term demand and pricing risk: CEO Mike Doustdar warned up to ~1.5M U.S. patients may be using compounded (unapproved, cheaper) GLP‑1 alternatives — that substitution can blunt uptake of branded products and pressure pricing if regulators or payers don’t constrain the compounding market. Read More.
• Negative Sentiment: Analyst caution on valuation and execution: Several commentaries urge caution despite investor confidence — potential overextension in the stock, reliance on continued rapid adoption, and execution risk around pharmacy rollout and payer coverage could cap upside. Read More.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.